Jupiter neurosciences inc JUNS.US Overview Analysis
JUNS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
JUNS Current Performance
-0.50%
Jupiter neurosciences inc
4.68%
Avg of Sector
-0.39%
S&P500
Top 10 High Relevance to JUNS
- OSTX Os therapies incValue -Trend 2Swing Trading 2Whale Interest 1Dividend 1See more
JUNS Profile
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer's disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. It has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.